Replimune stock surges 127% on FDA panel support for melanoma drug

Replimune announced a favorable outcome for its melanoma drug following an FDA advisory committee meeting.

The FDA's Cellular, Tissue and Gene Therapies Advisory Committee reviewed the drug.

Replimune's stock soared 127% after hours.

The advisory committee's favorable outcome is a positive development for the drug's approval process.